Charles River Laboratories International (CRL) Debt to Equity (2016 - 2025)
Historic Debt to Equity for Charles River Laboratories International (CRL) over the last 17 years, with Q3 2025 value amounting to $0.64.
- Charles River Laboratories International's Debt to Equity rose 430.95% to $0.64 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.64, marking a year-over-year increase of 430.95%. This contributed to the annual value of $0.65 for FY2024, which is 1206.96% down from last year.
- As of Q3 2025, Charles River Laboratories International's Debt to Equity stood at $0.64, which was up 430.95% from $0.69 recorded in Q2 2025.
- Over the past 5 years, Charles River Laboratories International's Debt to Equity peaked at $1.19 during Q3 2021, and registered a low of $0.61 during Q3 2024.
- For the 5-year period, Charles River Laboratories International's Debt to Equity averaged around $0.87, with its median value being $0.82 (2023).
- As far as peak fluctuations go, Charles River Laboratories International's Debt to Equity soared by 1235.74% in 2021, and later plummeted by 3197.59% in 2023.
- Quarter analysis of 5 years shows Charles River Laboratories International's Debt to Equity stood at $1.05 in 2021, then dropped by 13.51% to $0.91 in 2022, then decreased by 19.09% to $0.73 in 2023, then fell by 12.07% to $0.65 in 2024, then decreased by 0.82% to $0.64 in 2025.
- Its Debt to Equity was $0.64 in Q3 2025, compared to $0.69 in Q2 2025 and $0.78 in Q1 2025.